Maia Biotechnology

MAIA Biotechnology accelerates its Phase 3 trial for a novel telomere-targeting therapy in advanced non-small cell lung cancer. The study evaluates the treatment as a third-line option, showing strong patient enrollment and dosing progress. This pivotal trial assesses efficacy and safety in late-stage lung cancer patients.

Jun 2026BioSpaceNews article

MAIA Biotechnology reports strong efficacy data for its ateganosine treatment in third-line non-small cell lung cancer (NSCLC), increasing confidence in its pivotal Phase 3 trial. The company outlines key clinical milestones planned for 2026 to further its development pipeline. Growth momentum is driven by the drug’s potential to address unmet needs in late-stage lung cancer therapy.

Jan 2026BioSpaceNews article

MAIA Biotechnology’s ateganosine, a first-in-class telomere-targeting therapy, demonstrates strong clinical results in advanced non-small cell lung cancer (NSCLC). The company’s ongoing Phase 2 trial and newly initiated Phase 3 program highlight growing interest in the drug’s potential. Ateganosine targets telomeres, a novel approach in oncology.

Dec 2025BioSpaceNews article

MAIA Biotechnology expands its Phase 2 THIO-101 trial for ateganosine, now enrolling patients in additional countries. The company reports 12 participants enrolled to date as part of the trial’s ongoing momentum. This development is highlighted at the Society for Immunotherapy of Cancer (SITC) 2025 conference.

Nov 2025nasdaq.comNews article